Meeting
2022 ASCO Annual Meeting
Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).
Authors
Annika Kurreck
Charité– Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CVK), Berlin, Germany
Annika Kurreck , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Lothar Mueller , Alexander Koenig , Ludwig von Weikersthal , Eray Goekkurt , Siegfried Haas , Arndt Stahler , Volker Heinemann , Swantje Held , Annabel Helga Sophie Alig , Beeke Hoppe , Andreas Jay Kind , Stefan Kasper , Sebastian Stintzing , Tanja Trarbach , Dominik Paul Modest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01991873
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3587)
DOI
10.1200/JCO.2022.40.16_suppl.3587
Abstract #
3587
Poster Bd #
381
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).
First Author: Beeke Hoppe
Poster
2022 ASCO Annual Meeting
Negative hyperselection for mutations associated with anti-EGFR antibody resistance in RAS wildtype metastatic colorectal cancer (mCRC): Evaluation of the PANAMA trial (AIO-KRK-0212, maintenance therapy with 5-FU, folinic acid (FU/FA) with or without panitumumab).
First Author: Andreas Jay Kind
Poster
2015 Gastrointestinal Cancers Symposium
A phase II trial of panitumumab with irinotecan and S-1 (IRIS) as second-line treatment in patients with wild-type KRAS metastatic colorectal cancer.
First Author: Rai Shimoyama
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando